New Risk • Jun 02
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Earnings have declined by 3.9% per year over the past 5 years. Announcement • May 29
Gufic Biosciences Limited Recommends Final Dividend for the Financial Year 2025-26 The board of directors of Gufic Biosciences Limited at its meeting held on May 29, 2026, Recommendation of Final Dividend @10% i.e. INR 0.10 per equity share (Face Value of INR 1 each) for the Financial Year 2025-26, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Valuation Update With 7 Day Price Move • May 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹326, the stock trades at a trailing P/E ratio of 65.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past three years. Announcement • May 22
Gufic Biosciences Limited to Report Q4, 2026 Results on May 29, 2026 Gufic Biosciences Limited announced that they will report Q4, 2026 results on May 29, 2026 Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹1.24 (vs ₹1.93 in 3Q 2025) Third quarter 2026 results: EPS: ₹1.24 (down from ₹1.93 in 3Q 2025). Revenue: ₹2.32b (up 12% from 3Q 2025). Net income: ₹124.2m (down 36% from 3Q 2025). Profit margin: 5.4% (down from 9.3% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Feb 09
Gufic Biosciences Limited to Report Q3, 2026 Results on Feb 13, 2026 Gufic Biosciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 13, 2026 Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹1.68 (vs ₹2.17 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.68 (down from ₹2.17 in 2Q 2025). Revenue: ₹2.39b (up 17% from 2Q 2025). Net income: ₹168.2m (down 23% from 2Q 2025). Profit margin: 7.0% (down from 11% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Announcement • Nov 08
Gufic Biosciences Limited to Report Q2, 2026 Results on Nov 14, 2025 Gufic Biosciences Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Sep 30
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2025 Gufic Biosciences Limited in its Annual General Meeting of the Company held on September 29, 2025 approved a final dividend @ 10% i.e., INR 0.10/- per equity share of the face value of INR 1/- each for the Financial Year ended March 31, 2025. Declared Dividend • Sep 06
Dividend of ₹0.10 announced Dividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 1st January 1970 Dividend yield will be 0.03%, which is lower than the industry average of 0.8%. Payout Ratios Payout ratio: 1%. Cash payout ratio: 2%. Announcement • Sep 05
Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2025 Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2025, at 15:30 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹1.30 (vs ₹2.08 in 1Q 2025) First quarter 2026 results: EPS: ₹1.30 (down from ₹2.08 in 1Q 2025). Revenue: ₹2.25b (up 11% from 1Q 2025). Net income: ₹130.7m (down 37% from 1Q 2025). Profit margin: 5.8% (down from 10% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Announcement • Aug 09
Gufic Biosciences Limited to Report Q1, 2026 Results on Aug 13, 2025 Gufic Biosciences Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • May 31
Full year 2025 earnings released: EPS: ₹6.95 (vs ₹8.74 in FY 2024) Full year 2025 results: EPS: ₹6.95 (down from ₹8.74 in FY 2024). Revenue: ₹8.23b (up 2.1% from FY 2024). Net income: ₹696.5m (down 19% from FY 2024). Profit margin: 8.5% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Announcement • May 23
Gufic Biosciences Limited to Report Q4, 2025 Results on May 30, 2025 Gufic Biosciences Limited announced that they will report Q4, 2025 results on May 30, 2025 Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: ₹1.93 (vs ₹2.23 in 3Q 2024) Third quarter 2025 results: EPS: ₹1.93 (down from ₹2.23 in 3Q 2024). Revenue: ₹2.10b (up 3.9% from 3Q 2024). Net income: ₹193.1m (down 13% from 3Q 2024). Profit margin: 9.2% (down from 11% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Announcement • Feb 09
Gufic Biosciences Limited to Report Q3, 2025 Results on Feb 14, 2025 Gufic Biosciences Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Board Change • Nov 25
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Kamal Seth was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 22
Gufic Biosciences Limited Announces Cessation of Gopal Madhavbhai Daptari as Independent Director Gufic Biosciences Limited informed that the second and final term of Mr. Gopal Madhavbhai Daptari as an Independent Director ends on November 23, 2024. Consequently, he shall cease to be an Independent Director of the Company with effect from the close of business hours on November 23, 2024. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹2.39 in 2Q 2024) Second quarter 2025 results: EPS: ₹2.17 (down from ₹2.39 in 2Q 2024). Revenue: ₹2.04b (down 5.0% from 2Q 2024). Net income: ₹217.7m (down 6.2% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Announcement • Nov 09
Gufic Biosciences Limited to Report Q2, 2025 Results on Nov 14, 2024 Gufic Biosciences Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Announcement • Sep 26
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2024 Gufic Biosciences Limited at its 40th Annual General Meeting held on September 25, 2024, approved to declare a Final Dividend at the rate of 10% i.e., INR 0.10 per equity share of the face value of INR 1 each for the Financial Year ended March 31, 2024. Announcement • Sep 25
Gufic Biosciences Limited Announces Cessation of Shreyas Patel as Independent Director and New Composition of Committees Gufic Biosciences Limited at its Board of Directors Meeting, held on September 25, 2024, announced the completion of second term of Mr. Shreyas Patel, Independent Director of the Company, effective from the close of business hours on September 25, 2024. Consequently, he would also cease to hold Membership in the Audit Committee, Nomination & Remuneration Committee, Corporate Social Responsibility Committee and Risk Management Committee of the Company with effect from the close of business hours on September 25, 2024. Reason for change: Cessation due to completion of second and final term as an Independent Director. In light of the cessation of Mr. Shreyas Patel as a Member of the AC, NRC and RMC, the Board has approved reconstitution of the aforementioned committees. The new composition of the said Committees with effect from September 26, 2024 shall be as follows: Audit Committee: Mr. Gopal Daptari - Chairperson Non Executive Independent Director, Dr. Anu Aurora - Member Non Executive Independent Director, Mr. Jayesh Choksi - Member Executive Director and Mr. Kamal Kishore Seth - Member Non Executive Independent Director. Nomination & Remuneration Committee: Dr. Anu S. Aurora - Chairperson Non Executive Independent Director, Mr. Gopal Daptari - Member Non Executive Independent Director and Mr. Kamal Kishore Seth - Member Non Executive Independent Director. Risk Management Committee: Mr. Jayesh Choksi - Chairperson Executive Director, Mr. Pranav Choksi - Member Executive Director, Mr. Gopal Daptari - Member Non Executive Independent Director, Dr. Anu Aurora - Member Non Executive Independent Director, Mr. Devkinandan Roonghta - Chief Financial Officer Member, Mr. Nagesh Yarrabathina Member Chief Operating Officer and Mr. Ashok Dev - Member President - Operations. Declared Dividend • Sep 04
Dividend of ₹0.10 announced Dividend of ₹0.10 is the same as last year. Ex-date: 18th September 2024 Payment date: 25th October 2024 Dividend yield will be 0.02%, which is lower than the industry average of 0.8%. Announcement • Aug 29
Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024 Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024, at 15:30 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2025 earnings released: EPS: ₹2.08 (vs ₹2.13 in 1Q 2024) First quarter 2025 results: EPS: ₹2.08. Revenue: ₹2.04b (up 4.6% from 1Q 2024). Net income: ₹208.6m (up 1.1% from 1Q 2024). Profit margin: 10% (in line with 1Q 2024). Announcement • Aug 14
Gufic Biosciences Limited Announces Resignation of Bal Ram Singh as Non-Executive and Non-Independent Director Gufic Biosciences Limited announced that at the Board of Directors meeting held on August 14, 2024, approved Resignation of Dr. Bal Ram Singh (DIN: 06918085) from the position of Non-Executive and Non-Independent Director of the Company due to his preoccupation, with effect from the close of business hours on August 14, 2024. Announcement • Aug 09
Gufic Biosciences Limited to Report Q1, 2025 Results on Aug 14, 2024 Gufic Biosciences Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Announcement • Jun 29
Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee Gufic Biosciences Limited announced that second term of Dr. Rabi Sahoo (DIN: 01237464) as an Independent Director ends on June 28, 2024. Consequently, he shall be ceased to be an Independent Director of the Company with effect from the closing of business hours on June 28, 2024. Since the above change is due to completion of existing term, requirement of Resignation Letter is not applicable in this case. it is hereby informed that he would be ceased to be the Chairman of Stakeholders Relationship Committee and Member of Audit Committee with effect from the closing of business hours on June 28, 2024. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹376, the stock trades at a trailing P/E ratio of 43.7x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 105% over the past three years. Announcement • May 30
Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24 Gufic Biosciences Limited announced Board Meeting Outcome for Meeting Held On May 29, 2024 proposed recommendation of final dividend @ 10% that is INR 0.10 per equity share (Face Value of INR 1/each) for the Financial Year 202324, subject to the approval of the Shareholders at the upcoming Annual General Meeting of the Company. Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023) Full year 2024 results: EPS: ₹8.74 (up from ₹8.22 in FY 2023). Revenue: ₹8.09b (up 17% from FY 2023). Net income: ₹861.4m (up 8.1% from FY 2023). Profit margin: 11% (in line with FY 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023) Third quarter 2024 results: EPS: ₹2.23 (up from ₹2.10 in 3Q 2023). Revenue: ₹2.02b (up 14% from 3Q 2023). Net income: ₹222.6m (up 9.4% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.39 (up from ₹2.09 in 2Q 2023). Revenue: ₹2.15b (up 23% from 2Q 2023). Net income: ₹232.1m (up 15% from 2Q 2023). Profit margin: 11% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 12
Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited On October 11, 2023, Gufic Biosciences Limited, closed the transaction. Motilal Oswal Financial Services Limited acquired 3.32% in the transaction. Upcoming Dividend • Sep 14
Upcoming dividend of ₹0.10 per share Eligible shareholders must have bought the stock before 21 September 2023. Payment date: 29 October 2023. Payout ratio is a comfortable 1.2% but the company is not cash flow positive. The company last paid an ordinary dividend in May 2013. The average dividend yield among industry peers is 0.9%. Announcement • Sep 03
Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023 Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023, at 15:30 Indian Standard Time. Agenda: To consider and approve the aforementioned Preferential Issue. New Risk • Sep 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023) First quarter 2024 results: EPS: ₹2.13 (down from ₹2.17 in 1Q 2023). Revenue: ₹1.96b (up 19% from 1Q 2023). Net income: ₹206.2m (down 2.0% from 1Q 2023). Profit margin: 11% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 05
Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023 Gufic Biosciences Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹233, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 191% over the past three years. Announcement • May 31
Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023 Gufic Biosciences Limited recommended dividend at the rate of 10% i.e. INR 0.10 per equity share (face value of INR 1.00 each) for the financial year ended March 31, 2023, subject to the approval of the shareholders at the upcoming annual general meeting. Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022) Full year 2023 results: EPS: ₹8.22 (down from ₹9.89 in FY 2022). Revenue: ₹6.93b (down 11% from FY 2022). Net income: ₹797.0m (down 17% from FY 2022). Profit margin: 12% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022) Third quarter 2023 results: EPS: ₹2.10 (down from ₹2.17 in 3Q 2022). Revenue: ₹1.77b (up 3.1% from 3Q 2022). Net income: ₹203.4m (down 3.3% from 3Q 2022). Profit margin: 12% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 47% per year. Board Change • Jan 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 4 highly experienced directors. Additional Whole Time Director Dilip Ghosh was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.09 (down from ₹2.41 in 2Q 2022). Revenue: ₹1.75b (down 9.9% from 2Q 2022). Net income: ₹202.1m (down 13% from 2Q 2022). Profit margin: 12% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 47% per year. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022) Second quarter 2023 results: EPS: ₹2.09 (down from ₹2.41 in 2Q 2022). Revenue: ₹1.75b (down 9.9% from 2Q 2022). Net income: ₹202.1m (down 13% from 2Q 2022). Profit margin: 12% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year whereas the company’s share price has increased by 49% per year. Announcement • Sep 04
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022 Gufic Biosciences Limited announced that at its AGM held on September 2, 2022, the shareholders approved final dividend at 10% that is INR 0.10 per equity share of the face value of INR 1 each for the financial year ended March 31, 2022. Upcoming Dividend • Aug 17
Upcoming dividend of ₹0.10 per share Eligible shareholders must have bought the stock before 24 August 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 1.1% and this is well supported by cash flows. The company last paid an ordinary dividend in September 2011. The average dividend yield among industry peers is 1.0%. Reported Earnings • Aug 13
First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022) First quarter 2023 results: EPS: ₹2.17 (down from ₹3.22 in 1Q 2022). Revenue: ₹1.66b (down 34% from 1Q 2022). Net income: ₹210.5m (down 33% from 1Q 2022). Profit margin: 13% (in line with 1Q 2022). Over the last 3 years on average, earnings per share has increased by 51% per year whereas the company’s share price has increased by 54% per year. Announcement • Aug 07
Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022 Gufic Biosciences Limited announced that they will report Q1, 2023 results on Aug 11, 2022 Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improved over the past week After last week's 16% share price gain to ₹234, the stock trades at a trailing P/E ratio of 23.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 217% over the past three years. Announcement • Jun 07
Gufic Biosciences Limited Launches New Drug Delivery System Gufic Biosciences Limited has launched New Drug Delivery System: Dual Chamber Bags at affordable price for the first time in India. Contributing immensely to the government's ambitious Make in India drive, Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported in India at a very high cost to the patients. On the contrary, Gufic has not only launched high-quality Dual Chamber Bags at an affordable and pocket friendly price, these New Drug Delivery System products even have longer shelf -life. These Dual Chamber Bags launched by Gufic are 2-Chamber IV Bags made up of polypropylene (DEHP free) with a peelable aluminium foil allowing the storage of unstable drugs which needs reconstitution just before the administration to the patient. The peelable seal separates lyophilized (or powder) drug and its diluent. Moreover, the product complies with the US and EU pharmacopoeias and it is manufactured in ISO7 clean room under cGMP. Features and benefits of Dual Chamber Bags (DCBJ byGufic: It reduces risk of bloodstream infections and thereby ensures Patient's safety. Stability of the drug is much more inDCB rather than vials as it provides complete protection from light & moisture. The bag's closed system ensures that the product is sterile and avoids risks of contamination during handling. No Nitrosamines used- No risk of Cancer in diverse organs and tissues. DCB, tubing & twist-off port areDEHP free- No risk of Cancer, birth defects & other reproductive harms. Glue free-Eradicates the risk of interaction with drug product. Prefilled with intended dosage and diluent in 2 separate bags-Accurate dosing, easy handling, seal integrity and high stability. Individualized treatment regimens-Avoids hospital contamination & provides high stability and convenience- Thus significantly improving product quality & patient compliance. Provides high stability-Avoids leachability, free of airborne bacterial contaminants & needle stick injuries. One of the most important USPs of these ready-to-use Dual Chamber Bags by Gufic is that they prevent contamination and protects the potency and efficacy of the drug. These bags also offer ease of handling at the time of reconstitution and also help in avoiding the dilution errors since the drug is present with the exact required quantity of the diluent to be used. It can be reconstituted just before administration by simply peeling off the aluminium foil and folding & squeezing the bag, thus the diluent enters the drug chamber and mixes with the drug. It is then directly administered as IV infusion to the patient with the help of IV tubes. The company's lyophilized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments, among others. Its products are supplied to all the major hospital chains and leading medical facilities. Reported Earnings • May 22
Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021) Full year 2022 results: EPS: ₹9.89 (up from ₹4.56 in FY 2021). Net income: ₹958.4m (up 117% from FY 2021). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth. Announcement • May 21
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022 Gufic Biosciences Limited recommended dividend at the rate of 10% i.e. INR 0.10 per equity share (face value of INR 1 each) for the financial year ended March 31, 2022, subject to the approval of the shareholders at the upcoming annual general meeting. Buying Opportunity • May 02
Now 21% undervalued Over the last 90 days, the stock is up 9.4%. The fair value is estimated to be ₹319, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 49%. Announcement • Apr 12
Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial Gufic Biosciences Limited (Gufic) have received permission from Central Licensing Approving Authority, Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare for manufacture, sale and distribution of Isavuconazonium Sulfate API and finished formulation Isavuconazole for Injection 200 mg/vial. Isavuconazole for Injection 200 mg/vial is indicated for the treatment of patients having 18 years of age and older for the treatment of Invasive Aspergillosis and Invasive Mucormycosis. Buying Opportunity • Apr 07
Now 21% undervalued Over the last 90 days, the stock is up 6.6%. The fair value is estimated to be ₹320, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Earnings per share has grown by 49%. Announcement • Apr 06
Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1 Gufic Biosciences Limited (Gufic) have received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients requiring ventilator support (NIV as well as Mechanical Ventilation). Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 Clinical trial in adult patients with moderate-to-severe COVID-19. Immunocin Phase 3 Study was a, Multi-centric, Randomized, Placebo-Controlled, Double-Blind study in hospitalized adult patients with laboratory-confirmed moderate-to-severe COVID-19. The primary objective of the study was to assess and compare the efficacy of Thymosin -1 (T1) in combination with Standard of Care Treatment (SOC) versus placebo with SOC. The clinical results are as summarized below: All the first 105 patients who had taken at least one dose of study medication were taken into analysis. This study was designed to explore efficacy of Immunocin as a primary objective, in patients with moderate and severe COVID-19. Statistically significant (p value - 0.03) difference between two arms has been observed with respect to all cause mortality, where Immunocin Arm has 11.1% Death rate compare to 38.5% in Placebo Arm, with absolute risk difference of 27.4%. 96% patients in study arm have shown improvement after 7 days of treatment with Immunocin along with SOC in WHO's 8 point Ordinal score Vs 57% in placebo arm group. WHO Ordinal scale Comparison of the mean change from baseline on both arms shown to be statistically significant for moderate and severe COVID-19 (p-value Moderate- 0.002, Severe-0.001). Immunocin treatment compared to placebo, has shown 2 days less hospitalization and 4 less ventilator days in moderate and severe COVID-19 patients respectively. Thymosin 1 (Immunocin) is an endogenous polypeptide hormone secreted by thymic epithelial cells. As an immunomodulatory therapy, Thymosin 1 has been investigated in many diseases involving immune dysfunction (such as sepsis, cystic fibrosis, and hepatitis viral infection) and is associated with an improved patient outcome. Thymosin 1 increase T cell numbers by promoting T cell development and proliferation, enhance their function and prevents & corrects lymphopaenia. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 16% share price gain to ₹239, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 215% over the past three years. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹2.17 (up from ₹1.69 in 3Q 2021). Revenue: ₹1.72b (up 19% from 3Q 2021). Net income: ₹210.3m (up 60% from 3Q 2021). Profit margin: 12% (up from 9.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 49% per year whereas the company’s share price has increased by 48% per year. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 23% share price gain to ₹244, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 162% over the past three years. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 16% share price gain to ₹223, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 147% over the past three years. Reported Earnings • Nov 07
Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹1.94b (up 62% from 2Q 2021). Net income: ₹233.4m (up 43% from 2Q 2021). Profit margin: 12% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Sep 02
Upcoming dividend of ₹0.10 per share Eligible shareholders must have bought the stock before 09 September 2021. Payment date: 18 October 2021. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 16% share price gain to ₹218, the stock trades at a trailing P/E ratio of 47.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 85% over the past three years. Reported Earnings • Jun 06
Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹4.91b (up 37% from FY 2020). Net income: ₹442.3m (up 94% from FY 2020). Profit margin: 9.0% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year. Valuation Update With 7 Day Price Move • May 10
Investor sentiment improved over the past week After last week's 25% share price gain to ₹176, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 20% over the past three years. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 17% share price gain to ₹132, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total loss to shareholders of 6.0% over the past three years. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹116, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 2.5% over the past three years. Is New 90 Day High Low • Feb 22
New 90-day low: ₹109 The company is down 4.0% from its price of ₹114 on 24 November 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Feb 10
Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹1.45b (up 48% from 3Q 2020). Net income: ₹131.8m (up 88% from 3Q 2020). Profit margin: 9.1% (up from 7.2% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Feb 03
Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021 Gufic Biosciences Limited announced that they will report Q3, 2021 results on Feb 08, 2021 Is New 90 Day High Low • Jan 04
New 90-day high: ₹132 The company is up 47% from its price of ₹89.55 on 06 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Nov 13
Second quarter 2021 earnings released: EPS ₹2.10 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹1.23b (up 43% from 2Q 2020). Net income: ₹163.3m (up 280% from 2Q 2020). Profit margin: 13% (up from 5.0% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year and the company’s share price has also increased by 11% per year. Valuation Update With 7 Day Price Move • Nov 12
Market bids up stock over the past week After last week's 18% share price gain to ₹126, the stock is trading at a trailing P/E ratio of 79.8x, up from the previous P/E ratio of 67.9x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 44%. Valuation Update With 7 Day Price Move • Nov 02
Market bids up stock over the past week After last week's 19% share price gain to ₹109, the stock is trading at a trailing P/E ratio of 68.8x, up from the previous P/E ratio of 57.6x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 21%. Is New 90 Day High Low • Oct 30
New 90-day high: ₹103 The company is up 4.0% from its price of ₹98.15 on 31 July 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Upcoming Dividend • Oct 27
Upcoming Dividend of ₹0.05 Per Share Will be paid on the 11th of December to those who are registered shareholders by the 3rd of November. The trailing yield of 0.05% is below the top quartile of Indian dividend payers (2.3%), and is lower than industry peers (0.7%). Announcement • Jul 31
Gufic Biosciences Limited to Report Q4, 2020 Results on Jul 31, 2020 Gufic Biosciences Limited announced that they will report Q4, 2020 results on Jul 31, 2020 
